FGFR2 and infantile convulsions and choreoathetosis: A clinical study is evaluating futibatinib and reported activity of the agent in patients diagnosed with iCCA harboring FGFR2 fusions who developed resistance to BGJ398 or Debio1347, with some patients having secondary FGFR2 kinase mutations [62].